Related Experiment Video
Updated: May 22, 2026
10:15
A Preclinical Model to Assess Brain Recovery After Acute Stroke in Rats
Published on: November 6, 2019
Novel multi-functional nitrones for treatment of ischemic stroke
Yewei Sun1, Gaoxiao Zhang, Zaijun Zhang
1Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy, Guangzhou 510632, China.
Bioorganic & Medicinal Chemistry
|May 15, 2012
Summary
A novel pyrazine derivative, compound 21, demonstrates significant neuroprotective effects for ischemic stroke treatment. It combines antiplatelet and potent antiradical activities, offering a promising therapeutic strategy.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Ischemic stroke is a major public health concern requiring effective treatments.
- Combining thrombolytic/antiplatelet and neuroprotective agents enhances therapeutic outcomes.
- Agents with dual antiplatelet and antiradical properties present a promising treatment strategy.
Purpose of the Study:
- To synthesize and evaluate novel pyrazine derivatives for ischemic stroke therapy.
- To investigate the biological activities and mechanisms of action of these compounds.
- To identify a lead compound with superior neuroprotective and antiplatelet/antiradical properties.
Main Methods:
- Synthesis of a series of new pyrazine derivatives.
- In vitro and in vivo evaluation of neuroprotective effects.
- Assessment of antiplatelet activity against ADP-induced aggregation.
- Cell-free assays to determine antiradical scavenging efficacy against hydroxyl, superoxide, and peroxynitrite radicals.
Main Results:
- Compound 21, featuring two nitrone moieties, exhibited the most potent neuroprotective effects.
- Compound 21 significantly inhibited adenosine diphosphate (ADP)-induced platelet aggregation.
- Compound 21 demonstrated superior scavenging activity against hydroxyl radicals (·OH), superoxide radicals (O(2)(·-)), and peroxynitrite (ONOO(-)).
Conclusions:
- Compound 21 is a highly effective neuroprotective agent for ischemic stroke.
- Its dual action of inhibiting platelet aggregation and scavenging free radicals contributes to its therapeutic potential.
- This pyrazine derivative represents a promising candidate for further development in ischemic stroke treatment.
Related Concept Videos
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...